Search for dissertations about: "malignant blood disorders"
Showing result 1 - 5 of 15 swedish dissertations containing the words malignant blood disorders.
-
1. Computational biology of blood disorders: Patterns and algorithms
Abstract : The morphological and molecular characterization and of malignant blood disorders is pivotal to ensure a correct diagnosis, guide therapy, and, in the longer term, to identify their molecular causes. Over the past several years, new technology has increased our abilities to describe, typecast, and understand hematologic malignancies beyond what was previously possible. READ MORE
-
2. Quality of life in patients with malignant blood disorders : a clinical and methodological study
Abstract : The overall aim of this thesis was to evaluate and, improve measurements of, health-related quality of life (HRQL) in patients with malignant blood disorders. Patients undergoing autologous stem cell transplantation (SCT), long-term (>5 years) survivors of Hodgkin's lymphoma (HL) and a randomly selected control group were studied. READ MORE
-
3. Exploring the heterogeneity of the hematopoietic stem and progenitor cell pool in cord blood
Abstract : Hematopoietic stem cell transplantation (HSCT) is a curative treatment for a wide range of malignant and hereditary disorders. It is yet the only clinically established stem cell treatment. READ MORE
-
4. Risk and prognostic factors for malignant glioma
Abstract : Background: Glioblastoma is the most common and aggressive type of glioma and associated with poor prognosis. Apart from ionizing radiation and some rare genetic disorders, few aetiological factors have been identified for primary brain tumours. READ MORE
-
5. Outcome after allogeneic stem cell transplantation with special reference to non-malignant disorders, chimerism and graft cell composition
Abstract : The outcome for patients undergoing allogeneic stem cell transplantation (HSCT), a treatment for several severe malignant and non-malignant disorders with hematopoietic origin, is a balancing act between beneficiary effects and risk factors. Treatment success is still limited by excessive immune response, such as graft-versus-host–disease (GVHD) and graft failure (GF), or the lack thereof as in malignancy relapse or severe infections. READ MORE